AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yoon, J.
Right arrow Articles by Rahal, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yoon, J.
Right arrow Articles by Rahal, J. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2004, p. 753-757, Vol. 48, No. 3
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.3.753-757.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

In Vitro Double and Triple Synergistic Activities of Polymyxin B, Imipenem, and Rifampin against Multidrug-Resistant Acinetobacter baumannii

Jimmy Yoon,1 Carl Urban,1,2* Christian Terzian,1 Noriel Mariano,1 and James J. Rahal1,3

Infectious Disease Section, New York Hospital Queens, Flushing,1 Departments of Microbiology,2 Medicine, Weill Medical College of Cornell University, New York, New York3

Received 17 June 2003/ Returned for modification 12 September 2003/ Accepted 12 November 2003


   ABSTRACT
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Eight unrelated clinical Acinetobacter baumannii isolates resistant to all commonly used antibiotics were subjected to three-dimensional checkerboard microtiter plate dilution and time-kill studies at one-fourth of their MICs of polymyxin B, imipenem, and rifampin. Synergy was demonstrated with combinations of polymyxin B and imipenem, polymyxin B and rifampin, and polymyxin B, imipenem, and rifampin. Double combinations of polymyxin B and imipenem and of polymyxin B and rifampin were bactericidal for seven of eight isolates, and triple combinations were bactericidal for all isolates within 24 h. Future clinical studies using double and triple therapy with these antibacterials may provide an effective option against potentially lethal infection due to multiresistant Acinetobacter baumannii.


   INTRODUCTION
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
In recent years, Acinetobacter baumannii has emerged as one of the more ubiquitous antibiotic-resistant gram-negative nosocomial pathogens among critically ill patients (4, 23). Although the carbapenems, ampicillin-sulbactam, and amikacin have retained excellent in vitro and clinical activities against susceptible strains of A. baumannii, a growing number of reports have documented resistance to these antibacterials (1, 2, 10, 12-14, 16). As a result nontraditional agents, including polymyxin B and colistin, have been used to treat patients infected with multiresistant A. baumannii (6, 9, 15). However, pulmonary infections have not responded well to such monotherapy, and resistance has occurred among strains that have persisted during treatment (6, 15, 24).

In this communication, we describe the in vitro double and triple interactions of polymyxin B, imipenem, and rifampin against eight unique strains of multidrug-resistant A. baumannii using checkerboard microdilution and time-kill methods.


   MATERIALS AND METHODS
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Eight multidrug-resistant clinical strains of A. baumannii were obtained from the Clinical Microbiology Laboratory at New York Hospital Queens. All isolates had different pulsed-field gel electrophoresis patterns and were considered unrelated according to the criteria established by Tenover et al. (21). MICs of selected individual antibiotics were then determined using microdilution and E-test methods (AB Biodisk North America Inc., Piscataway, N.J.) by the Infectious Disease Research Laboratory. E-test metallo-beta-lactamase (E-test MBL) strips were used to detect the presence of molecular class B beta-lactamases (25). Rifampin and polymyxin B were obtained from Sigma (St. Louis, Mo.), and imipenem powder was supplied by Merck and Co. (Rahway, N.J.). MIC determinations were performed using checkerboard microdilution methods with Mueller-Hinton broth and a final inoculum of approximately 5 x 105 CFU/ml. Microdilution plates for evaluation of triple drug combinations were performed in the following manner. The first microtiter plate contained no imipenem and increasing concentrations of rifampin ranging from 0 to 32 µg/ml on the x axis and increasing concentrations of polymyxin B ranging from 0 to 32 µg/ml on the y axis. Each of the subsequent six plates contained a fixed concentration of imipenem ranging from 1 to 32 µg/ml with increasing concentrations of rifampin ranging from 0 to 32 µg/ml on the x axis and increasing concentrations of polymyxin B ranging from 0 to 32 µg/ml on the y axis. MICs and fractional inhibitory concentrations (FICs) were determined after 24 h of growth. The MIC was defined as the well in the microtiter plate with the lowest drug combination at which no visible growth was observed. A bactericidal effect was defined as >=99.9% killing of the starting inoculum. FICs of <1.0, 1.0, and >1.0 were used to define synergy, addition, and antagonism, respectively, according to previously published methods (3, 27). Time-kill studies were also performed according to earlier described techniques (7, 17). Escherichia coli strain ATCC 25922 was used as a control for all experiments. The limit of detection in these studies was 2 log10 CFU/ml. Three-dimensional isobolograms were generated using Surfer 8 (Golden Software, Inc., Golden, Colo.).


   RESULTS
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
The MICs of the three antibiotics studied for all eight isolates are shown in Table 1. All eight isolates with imipenem MICs of 32.0 µg/ml or >32.0 µg/ml did not demonstrate an eightfold MIC reduction in the presence of EDTA using the E-test MBL procedure and were presumed not to possess metallo-beta-lactamases, according to the manufacturer's specifications. The results of time-kill experiments using 0.25 µg of polymyxin B/ml, 0.5 µg of rifampin/ml, and 8.0 µg of imipenem/ml for the eight unique clinical isolates of A. baumannii tested in this study are also summarized in Table 1. All isolates were killed within 24 h using polymyxin B-imipenem-rifampin, one isolate showed regrowth with imipenem plus polymyxin B (isolate E), and one isolate showed regrowth with polymyxin B plus rifampin (isolate A). Using three-dimensional checkerboard microdilution with polymyxin B, rifampin, and imipenem, the combined concentrations of each antibiotic showing synergy and their sum FICs ({Sigma}FICs) of less than 1.0 against isolates A and B are presented in Table 2. Double combinations of polymyxin B (0.5 µg/ml) and imipenem (2.0 to 8 µg/ml) were synergistic against isolate A. Double combinations of polymyxin B (0.25 to 0.5 µg/ml) and imipenem (0.25 to 8.0 µg/ml) were synergistic against isolate B. Synergy was observed with a combination of polymyxin B and rifampin at concentrations of 0.5 µg/ml of each drug against isolate A. Double combinations of polymyxin B (0.25 to 0.5 µg/ml) and rifampin (0.03 to 0.5 µg/ml) were synergistic. Triple combinations of polymyxin B (0.12 to 0.5 µg/ml), rifampin (0.03 to 1.0 µg/ml), and imipenem (1.0 to 16.0 µg/ml) were also synergistic against isolates A and B. These results are also shown as three-dimensional isobolograms for isolates A and B (Fig. 1). The areas of concavity correspond to the aforementioned concentration ranges of double and triple combinations. The graphs of time-kill experiments using one-fourth MICs of each agent (0.25 µg of polymyxin B/ml, 0.5 µg of rifampin/ml, 8.0 µg of imipenem/ml) alone and in combination are shown for four isolates (A, B, E, and H) in Fig. 2.


View this table:
[in this window]
[in a new window]
  		TABLE 1. MICs of each antibiotic alone and time-kill results for the eight clinical A. baumannii isolates

 

View this table:
[in this window]
[in a new window]
  		TABLE 2. Individual and sum total FICs of the three antibiotics

 


View larger version (42K):
[in this window]
[in a new window]
  		FIG. 1. (A) Three-dimensional isobologram for A. baumannii isolate A. The areas on the isobologram showing depressions (concave sinks) that approach zero represent the greatest synergy ({Sigma}FIC <= 1.0). (B) Results for isolate B.

 


View larger version (39K):
[in this window]
[in a new window]
  		FIG. 2. Time-kill experiments using one-fourth the MIC of each agent (0.25 µg of polymyxin B/ml, 0.5 µg of rifampin/ml, and 8.0 µg of imipenem/ml) alone and in combination for isolates A, B, E, and H. The dotted lines indicate the lower limit of detection of 2 log10 CFU/ml.

 

   DISCUSSION
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Several in vitro and animal model studies have demonstrated synergy with polymyxin B plus rifampin or imipenem and with polymyxin B plus meropenem against multidrug-resistant A. baumannii (23, 26; N. X. Chin, B. Scully, and P. Della-Latta, Abstr. 38th Intersci. Conf. Antimicrob. Agents Chemother., abstr. E-56, 1998). Another study has shown synergy between polymyxin B and rifampin against Serratia marcescens isolates from infected patients, even though the isolates were resistant to each antibiotic alone (19). In vitro triple synergistic studies with polymyxin B, trimethoprim, and sulfonamide have shown efficacy against multidrug-resistant Burkholderia cepacia, as has the combination of polymyxin E (methane sulfonate, colistimethate), trimethoprim, and sulfamethoxazole against S. marcescens (20, 22).

In the present study, double combinations of polymyxin B plus imipenem and polymyxin B plus rifampin were bactericidal against seven out of eight isolates tested. The triple combination of polymyxin B-rifampin-imipenem was synergistic against all isolates by checkerboard and time-kill studies. In these studies FICs (concentrations or MICs of the antibiotics in the combination divided by the MIC of the antibiotic alone) were calculated for two- and three-drug combinations (Table 2). All MICs have been graphically represented in a three-dimensional isobologram (Fig. 1). Synergy for three antibiotics has been defined by several investigators as a fractional sum of <1.0 ({Sigma}FIC of <1.0) (3, 27). Plotted values showing concave surface areas on the isobolograms correspond to synergy, and convex areas represent antagonism (3, 27). The probable role of polymyxin B in such synergy is its rapid permeabilization of the outer membrane, allowing enhanced penetration and activity of both imipenem and rifampin. Synergy between polymyxin B or other peptide antibacterials and the carbapenems would be expected when carbapenem resistance is due to porin protein defects. Synergy may not be evident if the organism possesses significant carbapenemase activity due to class B beta-lactamases. Metallo-carbapenemases were most likely not contributing to imipenem resistance in the eight isolates, since EDTA using MBL strips did not reverse resistance. Numerous mechanisms other than class B enzymes have been implicated in carbapenem resistance in Acinetobacter, including other beta-lactamase classes, porin protein losses or their reduced expression, and penicillin-binding protein changes (8, 23).

Although the use of two or more agents is accepted as appropriate treatment of patients with tuberculosis or human immunodeficiency virus infection, this approach has not been tested in controlled clinical trials against multidrug-resistant Acinetobacter. However, it is known that the selection and isolation of mutants from existing populations of cells depend on a number of variables, including the bacterial inoculum at the site of infection, antibacterial agent(s) used, and mechanisms of resistance associated with targeted bacteria. It therefore seems reasonable to use at least two agents for treatment of selected patients infected with multidrug-resistant pathogens that have demonstrated mutation-related progressive resistance during single-drug therapy. Others have also suggested combination therapy as a tool to prevent the emergence of bacterial resistance and for improved outcomes in severely ill patients infected with gram-negative bacteria known to develop resistance on single therapy (5, 18).

Our studies showed that the combination of polymyxin B plus imipenem was as effective as polymyxin B plus rifampin and may provide an alternative for treatment even when Acinetobacter isolates are resistant to the carbapenems due to mechanisms other than metallo-carbapenemases. The addition of rifampin as a third component remains controversial. Synergy between colistin and rifampin has been reported previously in vitro (11). However, all except one of our eight isolates were killed within 24 h by imipenem and polymyxin B. Clinical trials will be necessary to determine whether combination therapy with two or three drugs is more effective than use of a single agent.


   ACKNOWLEDGMENTS
 
This work was supported by the BMA Medical Foundation, the Beatrice Snyder Foundation, and Agnes Varis.


   FOOTNOTES
 
* Corresponding author. Mailing address: New York Hospital Queens, 56-45 Main St., Flushing, NY 11355. Phone: (718) 670-1525. Fax: (718) 661-7899. E-mail: cmurban{at}nyp.org. Back


   REFERENCES
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Afzal-Shah, M., and D. M. Livermore. 1998. Worldwide emergence of carbapenem-resistant Acinetobacter. J. Antimicrob. Chemother. 41:576-577.[Free Full Text]
  2. Appleman, M. D., H. Belzberg, D. M. Citron, P. N. R. Heseltine, A. E. Yellin, J. Murray, and T. V. Berne. 2000. In vitro activities of non-traditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care breakout. Antimicrob. Agents Chemother. 44:1035-1040.[Abstract/Free Full Text]
  3. Berenbaum, M. C. 1978. A method for testing for synergy with any number of agents. J. Infect. Dis. 137:122-130.[Medline]
  4. Bergogne-Berezin, E., and K. J. Towner. 1996. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin. Microbiol. Rev. 9:148-165.[Medline]
  5. Chow, J. W., and V. L. Yu. 1999. Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int. J. Antimicrob. Agents 11:7-12.[CrossRef][Medline]
  6. Craig, A. W., and A. Reboli. 1993. Infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J. Infect. Dis. 168:1602-1603.[Medline]
  7. Eliopoulos, G. M., and R. C. Mollering, Jr. 1996. Antimicrobial combinations, p. 330-396. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. Williams & Wilkins, Baltimore, Md.
  8. Fernandez-Cuenca, F., L. Martinez-Martinez, M. C. Conejo, J. A. Ayala, E. J. Perea, and A. Pascual. 2003. Relationship between ß-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J. Antimicrob. Chemother. 51:565-574.[Abstract/Free Full Text]
  9. Fernandez-Viladrich, P., X. Corbella, L. Corral, F. Tubau, and A. Mateu. 1999. Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium. Clin. Infect. Dis. 28:916-917.[Medline]
  10. Giacometti, A., O. Cirioni, M. S. Del Prete, F. Barchiesi, A. Mataloni Paggi, E. Petrelli, and G. Scalise. 2000. Comparative activities of polycationic peptides and clinically used antimicrobial agents against multidrug-resistant nosocomial isolates of Acinetobacter baumannii. J. Antimicrob. Chemother. 46:807-810.[Abstract/Free Full Text]
  11. Giamarellos-Bourboulis, E. J., E. Xiruchaki, and H. Giamarellou. 2001. Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagn. Microbiol. Infect. Dis. 40:117-120.[CrossRef][Medline]
  12. Go, E., C. Urban, J. Burns, B. Kreiswirth, W. Eisner, N. Mariano, K. Mosinka-Snipas, and J. J. Rahal. 1994. Clinical and molecular epidemiology of Acinetobacter only to polymyxin B and sulbactam. Lancet 344:1329-1332.[CrossRef][Medline]
  13. Karlowsky, J. A., D. C. Draghi, M. E. Jones, C. Thornsberry, I. R. Friedland, and D. F. Sahm. 2003. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob. Agents Chemother. 47:1681-1688.[Abstract/Free Full Text]
  14. Levin, A. 2002. Multi-resistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem. Eur. J. Clin. Microbiol. Infect. Dis. 8:144.[CrossRef]
  15. Levin, A. S., A. A. Barone, J. Penco, M. V. Santos, I. S. Marinho, E. A. G. Arruda, E. I. Manrique, and S. F. Costa. 1999. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin. Infect. Dis. 28:1008-1011.[Medline]
  16. Manikul, V. M., D. Landman, G. Saurina, E. Oydna, H. Lai, and J. Quale. 2000. Endemic carbapenem resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, inter-institutional spread, and relation to antibiotic usage. Clin. Infect. Dis. 31:101-106.[CrossRef][Medline]
  17. Moody, J. A. 1992. Synergy testing: broth microdilution checkerboard and broth macrodilution methods, p. 5.18.1-5.18.23. In H. D. Eisenberg (ed.), Clinical microbiology procedures handbook. American Society for Microbiology, Washington, D.C.
  18. Mouton, J. W. 1999. Combination therapy as a tool to prevent emergence of bacterial resistance. Infection 27:S24-S28.
  19. Ostenson, R. C., B. T. Fields, and C. M. Nolan. 1977. Polymyxin B and rifampin: new regimens for multi-resistant Serratia marcescens infections. Antimicrob. Agents Chemother. 12:655-659.[Abstract/Free Full Text]
  20. Rahal, J. J., M. S. Simberkoff, and P. J. Hyams. 1973. Pseudomonas cepacia tricuspid endocarditis: treatment with trimethoprim, sulfonamide and polymyxin B. J. Infect. Dis. 128:S762-S767.
  21. Tenover, F. C., R. D. Arbeit, R. V. Goering, P. A. Mickelsen, B. E. Murray, D. H. Persing, and B. Swaminathan. 1995. Interpreting chromosomal DNA restriction patterns by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.[Medline]
  22. Thomas, F. E., Jr., J. M. Leonard, and R. H. Alford. 1976. Sulfamethoxazole-trimethoprim-polymyxin therapy of serious multiply drug-resistant Serratia infections. Antimicrob. Agents Chemother. 9:201-207.[Abstract/Free Full Text]
  23. Urban, C., S. Segal-Maurer, and J. J. Rahal. 2003. Considerations in control and treatment of nosocomial infection due to multi-drug-resistant Acinetobacter baumannii. Clin. Infect. Dis. 36:1268-1274.[CrossRef][Medline]
  24. Urban, C., N. Mariano, J. J. Rahal, E. Tay, C. Ponio, T. Koprivnjak, and J. Weiss. 2001. Polymyxin B-resistant Acinetobacter baumannii clinical isolates susceptible to recombinant BPI21 and cecropin P1. Antimicrob. Agents Chemother. 45:994-995.[Free Full Text]
  25. Walsh, T. R., A. Bolmström, A. Qwärnström, and A. Gales. 2002. Evaluation of a new E-test for detecting metallo-ß-lactamases in routine clinical testing. J. Clin. Microbiol. 40:2755-2759.[Abstract/Free Full Text]
  26. Wolff, M., M. L. Joly-Guillou, R. Farinotti, and C. Carbon. 1999. In vivo efficacies of combinations of ß-lactams, ß-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model. Antimicrob. Agents Chemother. 43:1406-1411.[Abstract/Free Full Text]
  27. Yu, V. L., T. P. Felegie, R. B. Yee, A. W. Pasculle, and F. H. Taylor. 1980. Synergistic interaction in vitro with use of three antibiotics simultaneously against Pseudomonas maltophilia. J. Infect. Dis. 142:602-607.[Medline]

Antimicrobial Agents and Chemotherapy, March 2004, p. 753-757, Vol. 48, No. 3
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.3.753-757.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yoon, J.
Right arrow Articles by Rahal, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yoon, J.
Right arrow Articles by Rahal, J. J.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS